Gerner R E, Moore G E, Dickey C
Oncology. 1975;31(1):22-30. doi: 10.1159/000225002.
Eighty-eight patients with disseminated melanoma and 22 patients with various other solid tumors were treated with combination chemotherapy consisting of DTIC, at a fixed dose, with either adriamycin, CCNU, or hydroxyurea, at several dosages. An objective response rate of 20% was observed in 84 evaluable melanoma patients. The addition of the other agents to DTIC did not provide enhanced antitumor activity. Combination chemotherapy increased toxicity. Encouraging objective responses were observed in patients with synovial sarcoma (4/7) and teratocarcinoma of the testis (1/1) treated with the combination of adriamycin and DTIC.
88例播散性黑色素瘤患者和22例患有各种其他实体瘤的患者接受了联合化疗,该联合化疗由固定剂量的达卡巴嗪(DTIC)与几种剂量的阿霉素、洛莫司汀(CCNU)或羟基脲组成。在84例可评估的黑色素瘤患者中观察到客观缓解率为20%。在DTIC中添加其他药物并未增强抗肿瘤活性。联合化疗增加了毒性。在用阿霉素和DTIC联合治疗的滑膜肉瘤患者(4/7)和睾丸畸胎癌患者(1/1)中观察到了令人鼓舞的客观缓解。